Products billed under this code include Fluzone High-Dose (2025/2026) (Preservative Free).
Payment limit per 0.5 ML, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Fluzone High-Dose (2025/2026) (Preservative Free) | Sanofi Pasteur | 49281-0125-65 | 10 | $1,225.22 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $122.522 | +$24.362 | 0.5 ML | Iiv no prsv increased ag im | v1, posted September 17, 2026 |
| 3Q26 | $98.16 | $0.00 | 0.5 ML | Iiv no prsv increased ag im | v1, posted September 15, 2026 |
| 2Q26 | $98.16 | $0.00 | 0.5 ML | Iiv no prsv increased ag im | v1, posted September 15, 2026 |
| 1Q26 | $98.16 | $0.00 | 0.5 ML | Iiv no prsv increased ag im | v1, posted September 15, 2026 |
| 4Q25 | $98.16 | +$14.668 | 0.5 ML | Iiv no prsv increased ag im | v1, posted September 8, 2026 |
| 3Q25 | $83.492 | $0.00 | 0.5 ML | Iiv no prsv increased ag im | v1, posted March 10, 2026 |
| 2Q25 | $83.492 | $0.00 | 0.5 ML | Iiv no prsv increased ag im | v1, posted March 10, 2026 |
| 1Q25 | $83.492 | $0.00 | 0.5 ML | Iiv no prsv increased ag im | v1, posted December 19, 2025 |
| 4Q24 | $83.492 | +$10.089 | 0.5 ML | Iiv no prsv increased ag im | v1, posted June 11, 2025 |
| 3Q24 | $73.403 | $0.00 | 0.5 ML | Iiv no prsv increased ag im | v1, posted June 11, 2025 |
| 2Q24 | $73.403 | $0.00 | 0.5 ML | Iiv no prsv increased ag im | v1, posted March 11, 2025 |
| 1Q24 | $73.403 | $0.00 | 0.5 ML | Iiv no prsv increased ag im | v1, posted December 19, 2024 |
| 4Q23 | $73.403 | +$3.462 | 0.5 ML | Iiv no prsv increased ag im | v1, posted October 10, 2024 |
| 3Q23 | $69.941 | $0.00 | 0.5 ML | Iiv no prsv increased ag im | v1, posted June 5, 2024 |
| 2Q23 | $69.941 | $0.00 | 0.5 ML | Iiv no prsv increased ag im | v1, posted February 23, 2024 |
| 1Q23 | $69.941 | $0.00 | 0.5 ML | Iiv no prsv increased ag im | v1, posted December 6, 2023 |
| 4Q22 | $69.941 | +$4.68 | 0.5 ML | Iiv no prsv increased ag im | v1, posted June 22, 2023 |
| 3Q22 | $65.261 | $0.00 | 0.5 ML | Iiv no prsv increased ag im | v1, posted June 9, 2023 |
| 2Q22 | $65.261 | $0.00 | 0.5 ML | Iiv no prsv increased ag im | v1, posted December 14, 2022 |
| 1Q22 | $65.261 | $0.00 | 0.5 ML | Iiv no prsv increased ag im | v1, posted June 8, 2022 |
| 4Q21 | $65.261 | +$4.279 | 0.5 ML | Iiv no prsv increased ag im | v1, posted June 2, 2022 |
| 3Q21 | $60.982 | $0.00 | 0.5 ML | Iiv no prsv increased ag im | v1, posted June 2, 2022 |
| 2Q21 | $60.982 | $0.00 | 0.5 ML | Iiv no prsv increased ag im | v1, posted March 1, 2022 |
| 1Q21 | $60.982 | – | 0.5 ML | Iiv no prsv increased ag im | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
